{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:30:21Z","timestamp":1761744621169},"reference-count":40,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.043","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T07:45:26Z","timestamp":1509522326000},"page":"7042-7048","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil"],"prefix":"10.1016","volume":"35","author":[{"given":"Ana Cristina C.","family":"Frota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee H.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wania","family":"Pereira-Manfro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth S.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Hugo","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalita F.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucimar G.","family":"Milagres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina B.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006454-200101000-00008","article-title":"Clinical Trials Group Protocol Teams 051, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy","volume":"20","author":"Dankner","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.043_b0010","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/170.5.1279","article-title":"Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants","volume":"170","author":"Dickover","year":"1994","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imr.12074","article-title":"Immunology of pediatric HIV infection","volume":"254","author":"Tobin","year":"2013","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0020","first-page":"61","article-title":"Immunization of children at risk of infection with human immunodeficiency virus","volume":"81","author":"Moss","year":"2003","journal-title":"Bull World Health Organ"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.043_b0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1473-3099(04)01106-5","article-title":"Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children","volume":"4","author":"Obaro","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.043_b0030","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.043_b0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1473-3099(10)70116-X","article-title":"Do children infected with HIV receiving HAART need to be revaccinated?","volume":"10","author":"Sutcliffe","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/imr.12067","article-title":"Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals","volume":"254","author":"Moir","year":"2013","journal-title":"Immunol Rev"},{"issue":"35","key":"10.1016\/j.vaccine.2017.10.043_b0045","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2014.06.015","article-title":"Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients","volume":"32","author":"Valour","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.043_b0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/INF.0b013e31828bbe68","article-title":"Undervaccination of perinatally HIV-infected and HIV-exposed uninfected children in Latin America and the Caribbean","volume":"32","author":"Succi","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.043_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jpids\/piu027","article-title":"Meningococcal disease: epidemiology and early effects of immunization programs","volume":"3","author":"S\u00e1fadi","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2017.10.043_b0060","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade, Secretaria deVigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. Manual dosCentros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. S\u00e9rie A. Normas e ManuaisT\u00e9cnicos. 3\u00aa ed. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2006."},{"key":"10.1016\/j.vaccine.2017.10.043_b0065","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Nota Informativa N\u00b0 311, de 2016\/CGPNI\/DEVIT\/SVS\/MS. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2016."},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.043_b0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/QAD.0b013e32833a2520","article-title":"Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2017.10.043_b0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12916-015-0538-6","article-title":"Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study","volume":"13","author":"Simmons","year":"2015","journal-title":"BMC Med"},{"issue":"37","key":"10.1016\/j.vaccine.2017.10.043_b0085","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.vaccine.2012.06.069","article-title":"Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults","volume":"30","author":"Bertolini","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.043_b0090","doi-asserted-by":"crossref","unstructured":"Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 2012; 161(4): 676-81.e2.","DOI":"10.1016\/j.jpeds.2012.04.005"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.043_b0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.10.043_b0105","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Manual dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. Bras\u00edlia:Minist\u00e9rio da Sa\u00fade; 2014."},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.043_b0110","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000000630","article-title":"Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil","volume":"34","author":"Frota","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.10.043_b0115","unstructured":"DAIDS Toxicity Grading Table of Adult and Pediatric Adverse Events v, December 2004, Clarification August 2009. http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf [accessed June 1]."},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.043_b0120","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med."},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.043_b0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.10.043_b0130","unstructured":"World Health Organization. WHO child growth standards length\/height-for-age,weight-for-age, weight-for-length, weight-for-height and body mass index-for-age:methods and development. Geneva, World Health Organization, 2006. <http:\/\/www.who.int\/childgrowth\/standards\/Technical_report.pdf> [accessed 07.07.16]."},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.043_b0135","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jped.2017.01.003","article-title":"Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus","volume":"93","author":"Frota","year":"2017","journal-title":"J Pediatr (Rio J)."},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.043_b0140","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/IAI.72.10.5903-5909.2004","article-title":"Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity","volume":"72","author":"Welsch","year":"2004","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.043_b0145","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.043_b0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.043_b0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00006454-200208000-00010","article-title":"Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children","volume":"21","author":"McVernon","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.043_b0160","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.043_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"24","key":"10.1016\/j.vaccine.2017.10.043_b0170","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1016\/S0264-410X(00)00050-5","article-title":"Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial","volume":"18","author":"Choo","year":"2000","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.043_b0175","doi-asserted-by":"crossref","first-page":"e100651","DOI":"10.1371\/journal.pone.0100651","article-title":"Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers","volume":"9","author":"Stoof","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.043_b0180","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1542\/peds.2011-2380","article-title":"Meningococcal conjugate vaccines policy update: booster dose recommendations","volume":"128","author":"Committee on Infectious Diseases","year":"2011","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.043_b0185","doi-asserted-by":"crossref","first-page":"e0145320","DOI":"10.1371\/journal.pone.0145320","article-title":"Early ART Results in Greater Immune Reconstitution Benefits in HIV-Infected Infants: Working with Data Missingness in a Longitudinal Dataset","volume":"10","author":"Azzoni","year":"2015","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.vaccine.2017.10.043_b0190","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1073\/pnas.0901702106","article-title":"Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children","volume":"106","author":"Pensieroso","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.043_b0195","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/INF.0000000000000144","article-title":"Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up","volume":"33","author":"Cagigi","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.043_b0200","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/jpids\/piw094","article-title":"Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth","volume":"6","author":"Warshaw","year":"2017","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T01:25:14Z","timestamp":1659749114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":40,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314512"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}